Could Ocugen Be a Millionaire-Maker Stock?
Ocugen (NASDAQ: OCGN) has been a rags-to-riches coronavirus stock with a stunning 3,830% return over the past year. The company rose to prominence after becoming the exclusive U.S. distribution partner of Indian coronavirus vaccine developer Bharat Biotech. In clinical trials, Bharat Biotech's coronavirus vaccine Covaxin showed 78% efficacy against COVID-19, has a good safety record, and can be stored for three months at room temperatures.
Covaxin has since received regulatory clearance in over 13 countries, with 300 million doses supplied to date. Ocugen seeks to be a part of that success by importing the vaccine from India for domestic use. Can this feat create wealth for investors? Or is the stock very overvalued?
Image source: Getty Images.
Source Fool.com
